SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).

被引：5
|
作者：
Chi, K. N.
De Bono, J. S.
Higano, C. S.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Hosp, Sutton, Surrey, England
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
    Porsch, Markus
    Ulrich, Matthias
    Wendler, Johann Jakob
    Liehr, Uwe-Bernd
    Reiher, Frank
    Janitzky, Andreas
    Baumunk, Daniel
    Schindele, Daniel
    Seseke, Florian
    Lux, Anke
    Schostak, Martin
    CHEMOTHERAPY, 2014, 60 (02) : 129 - 134
  • [22] Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Al Harthy, Munjid
    Petrylak, Daniel P.
    Kim, Joseph W.
    Arlen, Philip M.
    Rosner, Inger
    Theoret, Marc R.
    Cordes, Lisa
    Bilusic, Marijo
    Peer, Cody J.
    Dawson, Nancy A.
    Couvillon, Anna
    Hankin, Amy
    Williams, Moniquea
    Chun, Guin
    Owens, Helen
    Marte, Jennifer L.
    Lee, Min-Jung
    Tomita, Yusuke
    Yuno, Akira
    Trepel, Jane B.
    Lee, Sunmin
    Steinberg, Seth M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2021, 127 (04) : 435 - 444
  • [23] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
    Kelly, W. K.
    Halabi, S.
    Carducci, M. A.
    George, D. J.
    Mahoney, J. F.
    Stadler, W. M.
    Morris, M. J.
    Kantoff, P. W.
    Monk, J. P., III
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [24] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [25] PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (mCRPC)
    Mahon, Kate
    Lin, H-M
    Spielman, C.
    Lee-Ng, M.
    Gurney, H.
    Mallesara, G.
    Stockler, M.
    Briscoe, K.
    Marx, G.
    Breit, S. N.
    Brown, D.
    Horvath, L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 37 - 37
  • [26] Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
    Pal, Sumanta K.
    Lewis, Brian
    Sartor, Oliver
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 583 - +
  • [27] Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451)
    Heath, Elisabeth I.
    Mannuel, Heather Dorothy
    Liu, Glenn
    Lara, Primo
    Monk, J. P.
    Flaig, Thomas W.
    Zurita, Amado J.
    Vaishampayan, Ulka N.
    Stella, Philip J.
    Smith, Daryn W.
    Dobson, Kimberlee
    Hussain, Arif
    Al-Janadi, Anas
    Ivy, S. Percy
    Heilbrun, Lance K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [29] A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer
    Zhuang, Eric
    Uchio, Edward
    Lilly, Michael
    Zi, Xiaolin
    Fruehauf, John P.
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 143
  • [30] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345